ANTICANCER ACTIVITY PREDICTION OF GARCINIA MANGOSTANA L. vAGAINST HER2-POSITIVE BREAST CANCER THROUGH INHIBITING EGFR, HER2 AND IGF1R PROTEIN: A BIOINFORMATICS STUDY

Lifia Vania, Muhammad Hermawan Widyananda, Viol Dhea Kharisma, Arif Nur Muhammad Ansori, Sin War Naw, Nikolai Maksimiuk, Marina Derkho, Anastasia Denisenko, Nur Imaniati Sumantri, Alexander Patera Nugraha

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

HER2-positive breast cancer is known as the most aggressive and grows faster compared to other breast cancer types. In order to stop the maturation of the breast cancer cell type, the signaling pathways of the EGFR, IGF1R, and HER2 protein needs to be stopped. Garcinia mangostana L. has the potency to inhibit the activity of these proteins. The list of compounds in Garcinia mangostana L. was obtained from the KnapSack database. Drug-Likeness analysis was performed using SwissADME webserver. Specific molecular docking is done using AutoDock Vina. All the tested compounds contained in Garcinia mangostana L. have no violation of Lipinski rule and have good bioavailability. Several compounds have potential as EGFR, HER2, and IGF1R inhibitors. The most potent inhibitors of EGFR are 3-isomangostin and tovophyllin B. While, the potential inhibitors for HER2 are xanthone and 1,3,7-trihydroxy-2-dimethoxy xanthone, and lastly the potential inhibitors for protein IGF1R are tovophyllin A and tovophyllin B. This research informed that the observed anticancer activity of chemical compounds contained in Garcinia mangostana L. might be useful for developing cancer drugs against HER2-positive breast cancer.

Original languageEnglish
Pages (from-to)3313-3321
Number of pages9
JournalBiochemical and Cellular Archives
Volume21
Issue number2
Publication statusPublished - Oct 2021

Keywords

  • Cancer
  • EGFR
  • Garcinia mangostana L
  • HER2
  • IGF1R
  • non-communicable disease

Fingerprint

Dive into the research topics of 'ANTICANCER ACTIVITY PREDICTION OF GARCINIA MANGOSTANA L. vAGAINST HER2-POSITIVE BREAST CANCER THROUGH INHIBITING EGFR, HER2 AND IGF1R PROTEIN: A BIOINFORMATICS STUDY'. Together they form a unique fingerprint.

Cite this